TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05319639
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
Study: NCT05319639
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
Study: NCT05319639
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
Study: NCT05128773
Drug: Amcenestrant
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT05128773
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT05319639
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
Study: NCT05532449
Drug: Intravenous dizocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dizocine (0.03mg/kg diluted to 5 ml)
Study: NCT06435845
Drug: Anti-(integrin beta-3) human monoclonal antibody
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
Study: NCT05935774
Drug: Trabedersen (OT-101)
Normalized name: Trabedersen
DrugBank: Trabedersen (DB05697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05128773
Drug: Tamoxifen-matching placebo
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, oral
Study: NCT06173206
Drug: AS (Guilin Pharmaceuticals)
Normalized name: hydrocortisone
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Children will receive 4 mg/kg/day for 7 days
Study: NCT05966727
Drug: Cholestyramine Powder
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bile salt chelating resin, used as a lipid-lowering treatment.
Study: NCT06378047
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is an immunotherapy that will be administered via IV infusion.
Study: NCT05246280
Drug: TC99m-tilmanocept
Normalized name: technetium (99mTc) tilmanocept
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT06500598
Drug: Evinacumab
Normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04712539
Drug: Baloxavir Marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04712539
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05483439
Drug: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
Study: NCT06134362
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
Study: NCT06549608
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per product label
Study: NCT05370911
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms
Study: NCT05275023
Drug: JNJ-73763989
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 will be administered subcutaneously.
Study: NCT05275023
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor will be administered as IV infusion.
Study: NCT05275023
Drug: Tenofovir Disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil film-coated tablets will be administered orally.
Study: NCT05275023
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF film-coated tablets will be administered orally.
Study: NCT05275023
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV film-coated tablets will be administered orally.
Study: NCT06307808
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus
Study: NCT06387121
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-tumor alkaloids
Study: NCT06387121
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glucocorticoids
Study: NCT06387121
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
Study: NCT06387121
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A humanized monoclonal antibody-drug conjugate targeting CD22
Study: NCT06387121
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bi-specific anti-CD19/CD3 antibodies
Study: NCT06387121
Drug: 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cell cycle-specific antitumor drug
Study: NCT06387121
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pyrimidine antimetabolites
Study: NCT06387121
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoids
Study: NCT05447663
Drug: Siremadlin
Normalized name: Siremadlin
DrugBank: Siremadlin (DB16331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
Study: NCT05536752
Drug: QA102
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules
Study: NCT04732598
Drug: Paclitaxel + bevacizumab therapy
Normalized name: Paclitaxel
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Study: NCT04732598
Drug: Paclitaxel + bevacizumab + atezolizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Study: NCT06307808
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
Study: NCT06130007
Drug: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
Normalized name: platinum
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
Study: NCT05603741
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study: NCT05603741
Drug: Lidocaine Injection 2%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study: NCT05158387
Drug: Tozorakimab
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
Study: NCT05158387
Drug: Tozorakimab
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously tozorakimab Dose 2 through Week 52.
Study: NCT06047548
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06042855
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
Study: NCT05661357
Drug: Disitamab Vedotin Combined With Fruquintinib
Normalized name: Disitamab vedotin
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
Study: NCT05146154
Drug: Imipenem/Cilastatin/Relebactam 1.25g
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
Study: NCT05922904
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT05922904
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05922904
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05494411
Drug: Mitomycin for pyelocalyceal solution
Normalized name: mitomycin Powder for Pyelocalyceal Solution
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05469204
Drug: Midazolam oral solution
Normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg single-dose before and during estradiol treatment.
Study: NCT05469204
Drug: Digoxin Oral Tablet
Normalized name: digoxin Oral Tablet
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg single-dose before and during estradiol treatment.
Study: NCT05469204
Drug: Acetaminophen Oral Tablet
Normalized name: acetaminophen Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg single-dose before and during estradiol treatment.
Study: NCT05469204
Drug: Midazolam Injectable Solution
Normalized name: midazolam Injectable Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg intravenous single-dose before and during estradiol treatment.
Study: NCT06264310
Drug: R2R01
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Study: NCT05581875
Drug: Belantamab Mafodotin-Blmf
Normalized name: belantamab mafodotin-blmf
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
Study: NCT05581875
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
Study: NCT05581875
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered per os.
Study: NCT05581875
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered intravenously or per os.
Study: NCT05302648
Drug: Human Derived anti-BCMA CAR-T Injection
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Study: NCT06660368
Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
Study: NCT06660368
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be administered orally, once daily, with food.
Study: NCT05774639
Drug: Omalizumab Injection
Normalized name: omalizumab Injection
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
Study: NCT05718700
Drug: Bulevirtide
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Administered via subcutaneous (SC) injections
Study: NCT04807140
Drug: Toripalimab, nab-paclitaxel, carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04807140
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT06117046
Drug: 50 ml of normal saline intravenous infusion
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 ml of normal saline intravenous infusion
Study: NCT05143177
Drug: Evogliptin
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 5mg, 1 tab
Study: NCT05143177
Drug: Evogliptin
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-1229 10 mg, 1 tab
Study: NCT05098613
Drug: CD19x22 CAR T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
Study: NCT04527380
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT04527380
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT04910152
Drug: BRD4 Inhibitor PLX51107
Normalized name: Brd4 inhibitor plx51107
DrugBank: PLX51107 (DB17543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04829695
Drug: Artesunate-amodiaquine drug combination
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Study: NCT04777838
Drug: Citalopram 10 MG
Normalized name: citalopram 10 MG
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of citalopram every day
Study: NCT04777838
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg of Amitriptyline every
Study: NCT05172570
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
Study: NCT05848687
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
Study: NCT05848687
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05848687
Drug: PEG asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05848687
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05848687
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken PO or NG
Study: NCT05848687
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
Study: NCT05848687
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
Study: NCT05729568
Drug: Teropavimab
Normalized name: Teropavimab
DrugBank: Teropavimab (DB18916)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05729568
Drug: Zinlirvimab
Normalized name: Zinlirvimab
DrugBank: Zinlirvimab (DB18867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05729568
Drug: Lenacapavir Tablet
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05729568
Drug: Lenacapavir Injection
Normalized name: lenacapavir Injection
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT06503042
Drug: Chemotherapy combined with immunotherapy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
Study: NCT06111781
Drug: Relugolix 120 MG [Orgovyx]
Normalized name: relugolix 120 MG [Orgovyx]
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
Study: NCT06343935
Drug: Linperlisib
Normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
Study: NCT06511193
Drug: Budenoside/Glycopyrronium/Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
Study: NCT06427395
Drug: Saroglitazar Magnesium 1 mg
Normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
Study: NCT05038878
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
Study: NCT05065372
Drug: Metformin Hcl 1000Mg Tab
Normalized name: METFORMIN HCL 1000MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Agent used to modify insulin sensitivity
Study: NCT05065372
Drug: Aminohippurate Sodium 20 % Injection
Normalized name: aminohippurate sodium 20 % Injection
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance